Pemetrexed 500mg Injection Franchise in Ahmedabad

Antineoplastic Chemotherapy Supplier in Mumbai

Pemdrax 500 Injection Distributor in Delhi

Oncology Injection Franchise Opportunity in Bangalore

Cancer Therapy Injection Stockist in Hyderabad
Pemetrexed 500mg Export & Manufacturing in Chandigarh

Home/Products /pemetrexed-500mg-injection

About the Product

Description


Pemdrax 500 Injection contains Pemetrexed 500mg, a potent antineoplastic chemotherapy agent indicated for the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It plays a vital role in controlling tumor progression and improving treatment outcomes in advanced oncology care.

Pemetrexed acts by inhibiting multiple folate-dependent enzymes required for DNA and RNA synthesis in cancer cells, thereby suppressing cell division and inducing apoptosis. Its injectable formulation ensures precise dosing under supervised oncology protocols.

For distributors and healthcare suppliers, Pemdrax 500 Injection is a critical oncology therapy product, widely utilized in tertiary care hospitals, cancer specialty centers, and oncology clinics. The increasing global burden of lung cancer supports sustained demand in the oncology segment.

Adding Pemdrax 500 Injection to your oncology and anticancer therapy segment creates strong opportunities in hospital supply networks, specialty cancer institutions, export markets, and third-party manufacturing. Its proven clinical relevance, prescriber confidence, and essential role in chemotherapy regimens make it a valuable pharmaceutical offering.

Common side effects may include nausea, vomiting, fatigue, loss of appetite, mucositis, and bone marrow suppression leading to anemia, leukopenia, or thrombocytopenia. Rare but serious side effects include severe infections, renal toxicity, or hypersensitivity reactions. Immediate medical attention is required if severe adverse effects occur.

Pemdrax 500 Injection is indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination with other anticancer agents, as prescribed by an oncologist.

Pemdrax 500 Injection must be administered only by qualified healthcare professionals in a hospital or oncology setting. Folic acid and vitamin B12 supplementation are recommended to reduce treatment-related toxicity. Regular monitoring of blood counts and kidney function is essential throughout therapy.

Store Pemdrax 500 Injection in a cool, dry place between 2–8°C, protected from light. Keep out of reach of children. Use reconstituted solution immediately or as directed by the manufacturer. Do not use the injection beyond the expiry date printed on the vial.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Pemetrexed 500mg Injection in the PCD pharma franchise market?

Pemetrexed 500mg Injection has strong demand in the oncology, hospital care, and specialty healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on oncology and critical care portfolios.

Why should medical distributors include Pemetrexed 500mg Injection in their product range?

Medical distributors and agencies can benefit from demand for specialized oncology treatments administered under strict medical supervision. Pemetrexed 500mg is an antineoplastic (anticancer) medication belonging to the antifolate class Commonly prescribed for the treatment of certain types of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma as recommended by oncologists and treatment guidelines Used as part of comprehensive cancer treatment protocols, either alone or in combination with other anticancer therapies Requires administration and monitoring by qualified oncology professionals in specialized healthcare settings Frequently utilized in cancer hospitals, oncology centers, specialty clinics, and tertiary care institutions Widely prescribed by medical oncologists and cancer specialists This strengthens a comprehensive oncology and specialty care portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Pemetrexed 500mg Injection with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from institutional demand, oncology market opportunities, hospital procurement requirements, reliable supply chain support, and attractive margins in the specialty injectable segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and wholesalers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.